Efficacy and safety of perampanel in the subgroup of elderly patients included in the phase III epilepsy clinical trials

Ilo E. Leppik; Robert T. Wechsler; Betsy Williams; Haichen Yang; Sharon Zhou; Antonio Laurenza

doi:10.1016/j.eplepsyres.2014.11.015

Efficacy and safety of perampanel in the subgroup of elderly patients included in the phase III epilepsy clinical trials

Ilo E. Leppik, Robert T. Wechsler, Betsy Williams, Haichen Yang, Sharon Zhou, Antonio Laurenza

Experimental and Clinical Pharmacology

Research output: Contribution to journal › Article › peer-review

36 Scopus citations

Abstract

Clinical data regarding use of antiepileptic drugs in the elderly are generally scarce. Therefore, a subanalysis of subjects aged ≥65 years who participated in the 3 phase III perampanel studies was undertaken to determine efficacy and safety in these patients. Efficacy (change in seizure frequency/28 days and 50% responder rate) in the elderly subgroup was found to be consistent with the adult population. Adverse event rates were also largely similar, with some exceptions. Because risks of falls, dizziness, and fatigue were greater in the elderly, careful titration of perampanel in patients aged ≥65 years is suggested, especially at higher doses, where balancing tolerability and clinical response is necessary.

Original language	English (US)
Pages (from-to)	216-220
Number of pages	5
Journal	Epilepsy Research
Volume	110
DOIs	https://doi.org/10.1016/j.eplepsyres.2014.11.015
State	Published - Feb 1 2015

Bibliographical note

Funding Information:
Editorial support was funded by Eisai Inc. and provided by Imprint Publication Science, New York, NY, USA.

Publisher Copyright:
© 2014 The Authors.

Keywords

Adverse effects
Antiepileptic drugs
Efficacy
Elderly
Perampanel

Publisher link

10.1016/j.eplepsyres.2014.11.015

Find It

Find It at U of M Libraries

Cite this

@article{662a84c765f14b9ca720a46dbfdda548,

title = "Efficacy and safety of perampanel in the subgroup of elderly patients included in the phase III epilepsy clinical trials",

abstract = "Clinical data regarding use of antiepileptic drugs in the elderly are generally scarce. Therefore, a subanalysis of subjects aged ≥65 years who participated in the 3 phase III perampanel studies was undertaken to determine efficacy and safety in these patients. Efficacy (change in seizure frequency/28 days and 50% responder rate) in the elderly subgroup was found to be consistent with the adult population. Adverse event rates were also largely similar, with some exceptions. Because risks of falls, dizziness, and fatigue were greater in the elderly, careful titration of perampanel in patients aged ≥65 years is suggested, especially at higher doses, where balancing tolerability and clinical response is necessary.",

keywords = "Adverse effects, Antiepileptic drugs, Efficacy, Elderly, Perampanel",

author = "Leppik, {Ilo E.} and Wechsler, {Robert T.} and Betsy Williams and Haichen Yang and Sharon Zhou and Antonio Laurenza",

note = "Funding Information: Editorial support was funded by Eisai Inc. and provided by Imprint Publication Science, New York, NY, USA. Publisher Copyright: {\textcopyright} 2014 The Authors.",

year = "2015",

month = feb,

day = "1",

doi = "10.1016/j.eplepsyres.2014.11.015",

language = "English (US)",

volume = "110",

pages = "216--220",

journal = "Journal of Epilepsy",

issn = "0920-1211",

publisher = "Elsevier",

}

TY - JOUR

T1 - Efficacy and safety of perampanel in the subgroup of elderly patients included in the phase III epilepsy clinical trials

AU - Leppik, Ilo E.

AU - Wechsler, Robert T.

AU - Williams, Betsy

AU - Yang, Haichen

AU - Zhou, Sharon

AU - Laurenza, Antonio

PY - 2015/2/1

Y1 - 2015/2/1

N2 - Clinical data regarding use of antiepileptic drugs in the elderly are generally scarce. Therefore, a subanalysis of subjects aged ≥65 years who participated in the 3 phase III perampanel studies was undertaken to determine efficacy and safety in these patients. Efficacy (change in seizure frequency/28 days and 50% responder rate) in the elderly subgroup was found to be consistent with the adult population. Adverse event rates were also largely similar, with some exceptions. Because risks of falls, dizziness, and fatigue were greater in the elderly, careful titration of perampanel in patients aged ≥65 years is suggested, especially at higher doses, where balancing tolerability and clinical response is necessary.

AB - Clinical data regarding use of antiepileptic drugs in the elderly are generally scarce. Therefore, a subanalysis of subjects aged ≥65 years who participated in the 3 phase III perampanel studies was undertaken to determine efficacy and safety in these patients. Efficacy (change in seizure frequency/28 days and 50% responder rate) in the elderly subgroup was found to be consistent with the adult population. Adverse event rates were also largely similar, with some exceptions. Because risks of falls, dizziness, and fatigue were greater in the elderly, careful titration of perampanel in patients aged ≥65 years is suggested, especially at higher doses, where balancing tolerability and clinical response is necessary.

KW - Adverse effects

KW - Antiepileptic drugs

KW - Efficacy

KW - Elderly

KW - Perampanel

UR - http://www.scopus.com/inward/record.url?scp=84921264026&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84921264026&partnerID=8YFLogxK

U2 - 10.1016/j.eplepsyres.2014.11.015

DO - 10.1016/j.eplepsyres.2014.11.015

M3 - Article

C2 - 25616475

AN - SCOPUS:84921264026

SN - 0920-1211

VL - 110

SP - 216

EP - 220

JO - Journal of Epilepsy

JF - Journal of Epilepsy

ER -

Efficacy and safety of perampanel in the subgroup of elderly patients included in the phase III epilepsy clinical trials

Abstract

Bibliographical note

Keywords

Publisher link

Find It

Other files and links

Fingerprint

Cite this